US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (BBIO) ニュース

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BBIO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/30	05 : 01	GlobeNewswire Inc.	Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/24	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/18	05 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/15	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/14	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/13	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensiti	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/02	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/02	20 : 00	GlobeNewswire Inc.	BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/04/10	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/04/08	02 : 15	GlobeNewswire Inc.	BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/20	20 : 30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/07	07 : 15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/07	07 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/06	13 : 53	GlobeNewswire Inc.	BridgeBio Pharma Announces Pricing of Public Offering of Common Stock	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/05	07 : 25	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/05	06 : 17	GlobeNewswire Inc.	BridgeBio Pharma Announces Proposed Public Offering of Common Stock	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/04	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/04	16 : 30	GlobeNewswire Inc.	BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/23	06 : 27	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/22	21 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/22	21 : 30	GlobeNewswire Inc.	BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/22	06 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/21	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/16	06 : 06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/14	06 : 05	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/14	06 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/07	21 : 34	GlobeNewswire Inc.	BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/06	21 : 30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/05	21 : 30	GlobeNewswire Inc.	BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/02	21 : 00	GlobeNewswire Inc.	BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months	NASDAQ:BBIO	BridgeBio Pharma Inc

Showing the most relevant articles for your search:NASDAQ:BBIO

1 2 3 4 5 6 7 8 9 10 次へ >>

US Dollar vs Euro

US Dollar vs Yen

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約